# IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

> **NCT03175978** · PHASE1,PHASE2 · TERMINATED · sponsor: **IGF Oncology, LLC** · enrollment: 2 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Anemia, Refractory, With Excess of Blasts

## Interventions

- **DRUG:** IGF/MTX

## Key facts

- **NCT ID:** NCT03175978
- **Lead sponsor:** IGF Oncology, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-21
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03175978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03175978, "IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03175978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*